Amicus Therapeutics US, LLC
Philadelphia, PA Part of Amicus Therapeutics, Inc.
- UEI
- KLJFGENKMD89
- CAGE
- 867U3
- Primary NAICS
- 325412 Pharmaceutical Preparation Manufacturing
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- Corporate family
-
-
Amicus Therapeutics, Inc.
Parent
FJDHZ9PWMZ14
- Amicus Therapeutics US, LLC KLJFGENKMD89
-
Amicus Therapeutics, Inc.
Parent
FJDHZ9PWMZ14
- SAM.gov registration date
- Physical address
- 3675 Market St Fl 14, Philadelphia, PA 19104, USA
- Website
- amicusrx.com
- Founded
- 2002
- Employees
- 251-1K
- Estimated annual revenue
- $50M-$100M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Galafold 123 MG | Veterans Integrated Service Network 5 | $22,840 | |
| Galafold 123 MG | Veterans Integrated Service Network 5 | $22,840 | |
| Emergency galafold pharmacy drugs | Veterans Integrated Service Network 9 | $68,519 | |
| Migalastat 123 MG | Veterans Integrated Service Network 5 | $22,840 | |
| Galafold 123 MG | Veterans Integrated Service Network 5 | $22,840 |
About Amicus Therapeutics US, LLC
Amicus Therapeutics US, LLC, a subsidiary of publicly traded biopharmaceutical firm Amicus Therapeutics, Inc., supplies Galafold (migalastat) 123 mg capsules—an FDA-approved enzyme replacement therapy for Fabry disease treatment—to the Department of Veterans Affairs as a prime contractor under the GSA Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB). The vendor operates exclusively in the full-and-open market with no set-aside designation across its federal footprint. Based in Philadelphia, Pennsylvania, Amicus Therapeutics US, LLC is classified under NAICS 325412 (Pharmaceutical Preparation Manufacturing) and PSC Drugs and Biologicals, performing all work directly as prime with zero subcontractor involvement.
Customer concentration is extreme and single-agency focused. The Department of Veterans Affairs accounts for substantially all of Amicus Therapeutics US, LLC's federal work, spanning multiple Veterans Integrated Service Networks (VISNs). The top five VISNs by award count—VISN 5 (Mid-Atlantic), VISN 9, VISN 21, VISN 7, and VISN 19—collectively represent 97 percent of the 118 total awards in the source dataset. However, the potential-value ranking diverges sharply from the award-count ranking. VISN 12 anchors the top position with only three awards but carries $13.3 million in combined potential value (73.6 percent of all dollars), dominated by a single parent Federal Supply Schedule contract valued at $13.024 million awarded September 1, 2024, and effective through August 31, 2029. The remaining four high-volume VISNs—VISN 7, VISN 5, VISN 9, and VISN 19—together account for 115 awards with $4.7 million in combined potential value, reflecting the small individual task-order pattern typical of emergency and routine pharmaceutical procurement.
Amicus Therapeutics US, LLC holds a sole position on the GSA Pharmaceuticals and Drugs (FSS-61-IB) multiple-award schedule (contract 36F79724D0185), which serves as the parent vehicle for 114 of the vendor's 118 awards. The FSS contract, valued at $13.024 million and running through August 31, 2029, was awarded on September 1, 2024. Since that award, over 30 delivery orders have been issued across multiple VISNs, with individual task order ceilings ranging from approximately $18,500 to $295,000. The contract operates on a firm fixed-price basis with performance centered in Philadelphia, Pennsylvania, though recent orders show delivery locations spanning VISN regions including the Mid-Atlantic, Tennessee, and Pennsylvania areas.
Activity has grown modestly year over year—from 18 awards in 2022 to a peak of 31 in 2024, declining to 20 in 2025 and 11 through mid-2026. Three awards face ultimate completion dates within the next twenty-four months, carrying combined potential value of $592 thousand and representing minimal recompete exposure relative to the $13.024 million parent FSS contract, which does not expire until August 31, 2029.
The vendor's federal footprint is characterized by high-frequency, low-dollar transactional work. Delivery orders placed by individual VISNs typically have short performance periods—ranging from same-week to thirty-day fulfillment windows—reflecting emergency and routine pharmacy procurement patterns. Award descriptions consistently note both emergency pharmacy buys and routine supply requirements to support VA healthcare programs for veterans with Fabry disease. Combined dollars obligated to date total $4.7 million against $18 million in combined potential value (26 percent obligation rate), indicating significant remaining ceiling capacity under the parent FSS contract and active task-order pipeline.
Contract vehicles
Quick answers
What is Amicus Therapeutics US, LLC's UEI?
Amicus Therapeutics US, LLC's Unique Entity ID (UEI) in SAM.gov is KLJFGENKMD89.
What is Amicus Therapeutics US, LLC's CAGE code?
Amicus Therapeutics US, LLC's CAGE code is 867U3.
What is Amicus Therapeutics US, LLC's primary NAICS code?
Amicus Therapeutics US, LLC's primary NAICS code is 325412 (Pharmaceutical Preparation Manufacturing).
Where is Amicus Therapeutics US, LLC located?
Amicus Therapeutics US, LLC's physical address in SAM.gov is 3675 Market St Fl 14, Philadelphia, PA 19104, USA.
Is Amicus Therapeutics US, LLC registered in SAM.gov?
Yes. Amicus Therapeutics US, LLC's SAM.gov registration is active through February 6, 2027.
Who is Amicus Therapeutics US, LLC's parent company?
Amicus Therapeutics US, LLC is part of Amicus Therapeutics, Inc.
Which contract vehicles does Amicus Therapeutics US, LLC hold?
Amicus Therapeutics US, LLC holds a place on 1 federal contract vehicle: FSS-61-IB.
What is Amicus Therapeutics US, LLC's most recent federal award?
Amicus Therapeutics US, LLC's most recent federal contract award is Galafold 123 MG (36C24526N0881), from Veterans Integrated Service Network 5, on September 29, 2026.
On GovTribe
See Amicus Therapeutics US, LLC's full federal record
- Federal contract awards
- IDV awards
- Contract vehicles
- Funding analysis by agency, NAICS and set-aside
- Similar vendors